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CRISPR/Cas9 mediated knockout 
of rb1 and rbl1 leads to rapid 
and penetrant retinoblastoma 
development in Xenopus tropicalis
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Retinoblastoma is a pediatric eye tumor in which bi-allelic inactivation of the Retinoblastoma 1 (RB1) 
gene is the initiating genetic lesion. Although recently curative rates of retinoblastoma have increased, 
there are at this time no molecular targeted therapies available. This is, in part, due to the lack of highly 
penetrant and rapid retinoblastoma animal models that facilitate rapid identification of targets that 
allow therapeutic intervention. Different mouse models are available, all based on genetic deactivation 
of both Rb1 and Retinoblastoma-like 1 (Rbl1), and each showing different kinetics of retinoblastoma 
development. Here, we show by CRISPR/Cas9 techniques that similar to the mouse, neither rb1 nor 
rbl1 single mosaic mutant Xenopus tropicalis develop tumors, whereas rb1/rbl1 double mosaic mutant 
tadpoles rapidly develop retinoblastoma. Moreover, occasionally presence of pinealoblastoma 
(trilateral retinoblastoma) was detected. We thus present the first CRISPR/Cas9 mediated cancer model 
in Xenopus tropicalis and the first genuine genetic non-mammalian retinoblastoma model. The rapid 
kinetics of our model paves the way for use as a pre-clinical model. Additionally, this retinoblastoma 
model provides unique possibilities for fast elucidation of novel drug targets by triple multiplex CRISPR/
Cas9 gRNA injections (rb1 + rbl1 + modifier gene) in order to address the clinically unmet need of 
targeted retinoblastoma therapy.
Retinoblastoma (RB) is the most common pediatric tumor of the developing retina1. The initiating mutations 
are lesions in the Retinoblastoma 1 (RB1) tumor suppressor gene2. Statistical study of clinical retinoblastoma has 
led to the establishment of the two-hit hypothesis, stating that both RB1 alleles must be mutated in order for ret-
inoblastoma to develop3,4. Retinoblastoma can thus develop either in a heritable manner, due to a germline RB1 
mutation followed by a somatic RB1 inactivation, or in a sporadic manner due to two independent somatic RB1 
mutations. RB1 inactivation is also implicated in the initiation of other neoplasms including osteosarcoma, soft 
tissue cancer (spindle cell liposarcoma and atypical spindle cell lipoma) and small cell lung cancer, often in com-
bination with TP53 mutations5–8. Additionally, patients with germ-line RB1 mutations are at risk of developing 
trilateral retinoblastoma, a pediatric intracranial neuroblastic tumor9,10.
While treatment of unilateral retinoblastoma by modern therapies is usually curative, treatment of bilateral 
retinoblastoma with the aim to obtain survival, eye salvage and preservation of vision still represents a major 
challenge11. Treatment regimens have, however, recently improved and now routinely incorporate novel strategies 
such as ophthalmic artery chemosurgery, intravitreous chemotherapy and aggressive focal therapies12. However, 
no targeted molecular therapies exist within the clinic for treatment of retinoblastoma and this slow progress 
can be partly attributed to the lack of preclinical models that allow for rapid identification of druggable targets 
involved in the etiology of retinoblastoma13.
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Unlike the human situation, mice heterozygous for Rb1 do not develop retinoblastoma. Instead they 
develop a multiple endocrine neoplasia syndrome manifested by development of pituitary and thyroid tum-
ors14. Homozygous Rb1 mutants manifest embryonic lethality due to abnormalities in neural and hemato-
poietic development15,16. Murine retinoblastoma was first observed in chimeric animals lacking both Rb1 and 
Retinoblastoma-like 1 (Rb1/Rbl1), however the low recovery of viable chimeras precluded the generation of 
study-sized populations of retinoblastoma-bearing mice17. Current breedable murine retinoblastoma models 
depend on conditional deletion of the Rb1 gene using cre-transgenics on a Rbl1−/− (with or without a p53−/− or 
PTEN−/−) genetic background18–21. Whilst these latter cre-transgenic driven models exhibit high penetrance of 
retinoblastoma development, the latency is still relatively long (e.g. 100 ± 42.3 days in the Chx10-Cre; Rb1Lox/Lox; 
Rbl1−/−; p53−/− model), which has an impact on pre-clinical drug screening efforts13,22.
We have recently shown that targeted genome editing techniques, such as TALENs and CRISPR/Cas9, allow 
for cheap high-throughput gene knock-out approaches and modeling of cancer syndromes in the aquatic amphib-
ian model Xenopus tropicalis23. Importantly, unlike X. laevis and zebrafish, X. tropicalis has a true diploid genome 
that may facilitate modeling human genetic diseases, including cancer24,25.
Here we describe the first genuine genetic CRISPR/Cas9 mediated cancer model in X. tropicalis. We show 
rapid and penetrant retinoblastoma development in X. tropicalis, by co-targeting of rb1 and rbl1 with multi-
plex CRISPR/Cas9, closely recapitulating the histopathological hallmarks of clinical retinoblastoma. This model 
provides an interesting platform for pre-clinical drug screening efforts. Additionally this rapid model can be 
exploited for fast exploration of the impact of inactivating modifier or effector genes on the resulting phenotype 
by CRISPR/Cas9 multiplexing.
Results
Rb1 mosaic mutants develop normally and lack tumor formation. Two-cell stage X. tropica-
lis embryos were injected unilaterally with rb1 coding region 1 gRNA (rb1cr1) and recombinant Cas9 protein. 
Embryos were grown until stage 46 and pools of embryos were lysed and genomic DNA was extracted. The 
targeted region was amplified and successful insertion-deletion (INDEL) mutations in the rb1 locus (4%) were 
confirmed by targeted deep sequencing. Please note that due to the unilateral injection setup, this implies that 
one side across the ventral midline of the tadpole or froglet is 8% mosaic mutant, whereas the other side is essen-
tially wild-type. Efficiencies and variant calls for all next-generation sequencing experiments can be found as 
Supplementary Table S1.
We did not observe any histological or proliferation abnormalities (by proliferating cell nuclear antigen/PCNA 
staining) in the eyes of 7 days old mosaic rb1 mutant tadpoles (not shown). Furthermore, the eyes of four months 
old adult rb1 mosaics showed no abnormalities in retinal structure. Rb1 mosaics were raised up to sixteen months 
of age and none (n = 13) developed retinoblastoma distinguishable by gross examination. Together, these data 
indicate that, in contrast to the human situation, but in line with studies in the mouse, bi-allelic inactivation of the 
rb1 gene is insufficient for retinoblastoma development in Xenopus. Although the efficiencies of gene disruption 
were relatively low, we believe that if rb1 bi-allelic mutation was sufficient to initiate tumorigenesis, tumors would 
have been detected. This due to the expected selective growth advantage of this hypothetical population of rb1 
mutant tumor cells and the large original cohort size (n = 50).
Rbl1 mosaic mutants develop normally and lack tumor formation. Motivated by the studies in 
mice where it was shown that bi-allelic mutations in both the Rb1 and Rbl1 genes induced retinoblastoma, we 
wanted to investigate whether this was also the case in Xenopus. In order to ensure that rbl1 mutant animals 
are tumor-free, two-cell stage X. tropicalis embryos were unilaterally injected with rbl1 coding region 1 (rbl1cr1) 
gRNA. Embryos were grown until stage 46 and pools of embryos were lysed and genomic DNA was extracted. 
The targeted region was amplified and successful INDEL mutations in the rbl1 locus (26%) were confirmed by 
targeted deep sequencing. No retinoblastoma or histopathological abnormalities were detected in the eyes of 
post-metamorphic froglets (aged 58 days; n = 3). Rbl1 mosaic mutants (n = 5) were raised until 73 days of age, 
and none developed retinoblastoma distinguishable by gross examination.
Retinoblastoma and brain tumors rapidly develop in mosaic rb1/rbl1 mutant tadpoles and 
froglets. As we did not detect any retinoblastoma after inactivation of either rb1 or rbl1, we next performed 
multiplex genome editing by co-injections of two independent pairs of rb1 and rbl1 gRNAs. By employing two 
independent pairs of gRNAs, we circumvent possible development of phenotypes due to off-target effects of the 
CRISPR/Cas9 system, because it is highly unlikely that two distinct gRNAs will have an overlap in off-target 
profiles. Two-cell stage X. tropicalis embryos were unilaterally injected with either rb1cr1 and rbl1cr1 gRNA or 
rb1cr2 and rbl1cr2 gRNA together with recombinant Cas9 protein. Embryos were grown until stage 46 and pools of 
embryos were lysed and genomic DNA was extracted. Successful targeting of the loci was confirmed by targeted 
deep sequencing in the first setup (26% rb1 and 28% rbl1) as well as the second setup (9% rb1 and 10% rbl1).
Mosaic double rb1/rbl1 knockout tadpoles (MDKO tadpoles) rapidly developed externally visible eye tumors 
as early as 36 days post-injection. In total, MDKO tadpoles and frogs developed retinoblastomas ranging from 
smaller neoplasms, distinguishable only by increased size of one eye respectively to the other, to large retinoblas-
toma exhibiting leukocoria, ectopia lentis and tumor-associated neovasculature (Figs 1 and S1). Retinoblastomas 
exhibited rapid tumor progression, approximately doubling in size in seven days after being detected by gross 
examination. Some tadpoles also exhibited neurological symptoms such as abnormal swimming behavior, leth-
argy and reduced response to stimuli such as sound or touch. The animals were euthanized as soon as they 
showed clear signs of discomfort. The complete heads of tadpoles were dissected, decalcified and processed for 
histological analysis. Unilateral retinoblastoma was detected in 53% (n = 13; median 120 days) and 73% (n = 15; 
median 69 days) of the MDKO tadpoles for the rb1cr1/rbl1cr1 and rb1cr2/rbl1cr2 gRNA injections, respectively.
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These results are counterintuitive given the lower INDEL efficiency for the rb1cr2/rbl1cr2 set up. However, 
we postulate that these differences in retinoblastoma incidence are the consequence of the distinct targeting 
sites of the rbl1cr1 and rbl1cr2 gRNAs. The rbl1cr2 gRNA targets the pocket domain of the Rbl1 protein, a region 
of functional importance by binding E2F transcription factors, whilst the rbl1cr1 gRNA does not target a func-
tional domain. We believe that, in this region, small in-frame deletions or insertions, could still perturb protein 
function.
In addition to the retinal tumors, we were able to demonstrate brain neoplasms in 11% (n = 13) and 13% 
(n = 15) for rb1cr1/rbl1cr1 and rb1cr2/rbl1cr2 setups, respectively. These brain tumors can be the consequence of 
either locally invasive retinoblastoma or may represent discrete entities as intracranial midline tumors associated 
with the pineal gland (pinealoblastoma, trilateral retinoblastoma). Unfortunately, we were unable to confidently 
discriminate between these two possibilities, considering we have no tool to track the origin of these neoplasms.
Moreover, we have detected several other types of neoplasia in MDKO tadpoles, in particular small cell lung 
cancer, a choroid plexus neoplasm and one case of a hibernoma (Fig. S2). None of these were however detected 
more than once, and we thus consider MDKO tadpoles to be predisposed to several cancer types dependent on 
additional somatically acquired mutations.
Histological analysis confirms the presence of retinoblastoma histopathology. Histology 
revealed retinoblastoma appearing as a large basophilic mass that arises from, and destroys, the retina (Fig. 2a,b). 
It was observed that the retinoblastoma can seed into the vitreous cavity (endophytic growth pattern) and can 
exhibit areas of necrosis (orange arrowhead in Fig. 2b). Moreover, we also detected retinoblastoma arising from 
the outer layers of the retina exhibiting an exophytic growth pattern (Fig. 2c). Higher magnification investi-
gation revealed poorly differentiated neuroblastic cells that appear blue due to intensely basophilic nuclei and 
scant cytoplasm (small-blue-round-cell tumor) (Fig. 2a,b insets). Optic nerve invasion of small-blue-round-cells 
was also observed, demonstrating local spread of tumor cells (Fig. 2c,d). Ultimately, we plotted occurrence (and 
time-point) of retinoblastoma development by histopathological analysis (Fig. 3). Histological analysis of MDKO 
tadpoles, or froglets, also revealed large basophilic poorly differentiated small-blue-round-cell brain tumors, 
which were located across the midbrain and cranial midline (Fig. 4). As mentioned before, our model does not 
allow distinguishing between primary brain tumors and retinoblastoma metastasis. Nevertheless, due to the loca-
tion of a subset of brain neoplasms, which were located right across the cranial midline, we believe that we detect 
pinealoblastoma or trilateral retinoblastoma (Fig. 4b). Additionally, we also detected a pinealoblastoma in an 
animal which did not show retinoblastoma development upon histopathological assessment of the eyes.
Figure 1. Retinoblastoma 1 and retinoblastoma-like 1 CRISPR/Cas9 injected Xenopus tropicalis develop 
retinoblastoma. (a–c) Development of unilateral retinoblastoma can be externally observed in tadpoles 
injected with rb1 and rbl1 gRNAs, when comparing the eye on the uninjected side with the eye on the injected 
side in this tadpole. Leukocoria and ectopia lentis are apparent. (d) Unilateral retinoblastoma in a froglet.  
(e) Externally visible tumor-associated neovasculature.
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The neoplasms show extensive hyper proliferation. To further examine proliferation characteristics 
of the retinoblastoma and brain neoplasms of rb1cr1/rbl1cr1 MDKO tadpoles, we performed PCNA immunohisto-
chemistry. Nuclear PCNA staining was uniformly detected in the retinoblastoma nuclei whilst the adjacent retina 
remained quiescent (Fig. 5a,b). Additionally, PCNA positive tumor cells could be detected in a brain tumor and 
within the optic nerve of the injected side (Fig. 5), but not in the optic nerve of a wild-type eye (Fig. S3). Higher 
magnification of the invaded optic nerve clearly shows cycling cells within the optic nerve (Fig. 5). Next to this, 
PCNA staining was also uniformly detected in the brain tumor whereas the surrounding brain remained quies-
cent, with the exception of actively cycling cells in the subventricular zone (Fig. 5). PCNA immunohistochemistry 
Figure 2. Histopathology of retinoblastomas. (a–d) Examples of retinoblastomas observed in tadpoles 
and froglets injected with rb1 and rbl1 gRNAs. Under low magnification, retinoblastoma appears as a large 
basophilic mass with pink and purple foci. These tumor masses arise from and destroy the retina and can 
either fill part of the vitreous cavity, thus following an endophytic growth pattern (a,b) including necrotic areas 
(orange arrowhead), or can grow in the outer layers of the retina (exophytic growth pattern) (c). The poorly 
differentiated neuroblastic cells appear blue because they have intensely basophilic nuclei and scanty cytoplasm 
(‘small blue round cell tumor’) (inset a,b). The poorly differentiated neuroblastic cells show varying degrees of 
retinal differentiation with formation of (Homer Wright) rosettes. The tumors with exophytic growth can invade 
in the optic nerve (d). Scale bar sizes as follows; Blue scale bars are 200 μ m. Green scale bars are 20 μ m. Sections 






















Figure 3. Appearance of retinoblastoma. Graph indicating occurrence (and time-point) of retinoblastoma 
detection. Detection points either correspond to euthanasia of moribund tadpole/froglet with apparent 
retinoblastoma or with an end-point of the experiment (127 days for rb1cr1/rbl1cr1 and 69 days for rb1cr2/rbl1cr2). 
Each data point was validated by histopathological validation of the malignancy.
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on rb1cr2/rbl1cr2 MDKO tadpoles revealed identical proliferation characteristics of the neoplasms (Fig. S4). These 
immunohistochemical data validate the aggressive growth characteristics of the detected retinoblastoma, exhib-
iting local invasion and possibly distant metastasis.
Neoplasms are characterized by double bi-allelic rb1 and rbl1 mutations. In order to confirm that 
the retinoblastoma and brain tumors are clonal outgrowths of cells carrying mutations in both the rb1 and rbl1 
gene, we dissected an eye exhibiting retinoblastoma development and a normal looking eye from the injected 
side of a MDKO tadpole (Fig. S5). By targeted deep sequencing we showed that the normal appearing eye had rb1 
(26%) and rbl1 (22%) INDELs at levels similar to the general genome editing efficiency in the setup. In contrast, 
the retinoblastoma showed enrichment of INDELs in both rb1 (80%) and rbl1 (74%) loci. To further validate 
this, laser capture microdissection (LCM) was used to isolate retinoblastoma cells, adjacent normal retina, retina 
from the non-injected side and brain tumor (Fig. S6) from a histological section. Genomic DNA was extracted 
from these isolates, followed by targeted deep sequencing of the rb1cr1 and rbl1cr1 loci. The retinoblastoma was 
strongly enriched in two rb1 frameshift deletions (85%; Δ 52 and Δ 7) and an rbl1 insertion (58%; + 36). Note that 
these percentages do not reach 100% due to presence of pre-existing cells, blood cells and immune cells within 
the microdissected tissue. In contrast, the adjacent normal retina showed a lower level of rb1 deletion (16%; Δ 
30 and Δ 19) and rbl1 insertion (50%; + 1) . Additionally, the non-injected eye shows not a single INDEL in the 
rb1 locus and only a very basal level of rbl1 deletion (5%; Δ 15). The brain neoplasm, however, was also heavily 
enriched for rb1 frameshift deletion (89%; Δ 52 and Δ 7) and rbl1 insertion (97%; + 32). In order to validate this 
data, retinoblastoma and brain tumor were microdissected from a second tadpole from this cohort, attempting 
not to transfer any pre-existent cells (i.e. retinal pigment epithelium) (Fig. S7). By this method, almost universal 
rb1 and rbl1 INDELs (88% to 100%) could be demonstrated within the neoplasms (Table S1). This data implies 
that the neoplasms developing within the rb1/rbl1 MDKO tadpoles are discrete outgrowths of clones character-
ized by double bi-allelic mutations in rb1 and rbl1 as a consequence of the CRISPR/Cas9 genome editing. We 
observed, in some cases, only a single insertion in the rbl1 gene and this may indicate that loss of heterozygosity 
(LOH) occurred in the tumor. This needs further evaluation, but interestingly the occurrence of a very specific 
LOH in both the retinoblastoma as well as the brain tumor might indicate that this brain tumor is in fact clinically 
invaded retinoblastoma.
Triple multiplex gene disruption, facilitating therapeutic target identification, is possible 
within rb1cr2/rbl1cr2 Xenopus retinoblastoma model. In order to perform therapeutic target identifica-
tion in our model, we need to provide proof-of-principle for triple multiplex genome editing in Xenopus tropicalis. 
For this, we chose to target the spleen associated tyrosine kinase (SYK) gene, which was recently identified as a 
promising potential therapeutic target for molecularly targeted treatment of retinoblastoma26. Specifically, it was 
shown that the SYK gene is epigenetically deregulated and expressed at high levels in retinoblastoma thus pre-
venting programmed cell death through MCL126. However, Syk was not found to be epigenetically deregulated in 
murine retinoblastomas and subsequently the impact of a direct genetic knockout of SYK on retinoblastoma tum-
origenesis has not been investigated yet27. We unilaterally injected two cell stage Xenopus tropicalis embryos with 
rb1cr2, rbl1cr2, syk gRNA and recombinant Cas9 protein. Embryos were grown until stage 46 and pools of embryos 
were lysed and genomic DNA was extracted. We were able to demonstrate, by targeted deep sequencing, efficient 
Figure 4. Histopathology of brain tumors. (a,b) Low magnification shows large basophilic poorly 
differentiated small blue round cell tumors, which are located across the midbrain and cranial midline. Due to 
the location we believe we show a pinealoblastoma (trilateral retinoblastoma) in (b). Scale bar sizes as follows; 
Scale bars are 200 μ m. Section (a) has been cut longitudinal and section (b) has been cut transversal.
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genome modification of the rb1 (13%), rbl1 (10%) and syk (8%) loci. Please note that these efficiencies are more 
or less similar for all three loci. As this experiment only served as a pilot proof-of-principle, it only encompassed 
a very small number of animals (n = 10) and further work is evidently needed and will be performed to accurately 
identify the impact of syk knockout on retinoblastoma tumorigenesis.
Discussion
We describe a novel retinoblastoma model in Xenopus tropicalis that accurately recapitulates the clinical symp-
toms and the histopathological hallmarks of retinoblastoma. Progression also seems to closely mimic the clinical 
situation. This as we have detected in MDKO animals, small tumors, still confined to the retina, up to tumors 
Figure 5. Staining for a proliferation marker demonstrates aggressive growth characteristics of tumor cells 
in rb1cr1/rbl1cr1 MDKO tadpoles. Hoechst (left panels) and proliferating cell nuclear antigen (PCNA) (middle 
panels) double staining, with overlay in right panel. (a,b) PCNA staining is detected within the retinoblastoma 
(red arrowhead) whilst the adjacent normal retina remains quiescent (white arrowhead). In (b), tumor 
cells invading into the optic nerve (orange arrowhead) and a more distant metastasis (purple arrow) can be 
distinguished. (c) Higher magnification of the optic nerve clearly reveals PCNA positive tumor cells. (d) PCNA 
staining is uniformly detected within the brain tumor, whereas the surrounding normal brain tissue remains 
quiescent, with the exception of the subventricular zone. Scale bars are 200 μ M.
www.nature.com/scientificreports/
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exhibiting extensive vitreous chamber seeding and local invasion within the optic nerve. We provide some evi-
dence that this invasion can culminate in intracranial metastasis. Additionally, we suspect, due to location, the 
presence of trilateral retinoblastoma in at least one of the analyzed MDKO tadpoles and froglets. This low level of 
occurrence correlates well with the low clinical incidence of trilateral retinoblastoma28,29.
Setting up large clinical trials to validate novel treatment strategies is very hard due to the fact that the inci-
dence of retinoblastoma is low and the curative rates obtained by established therapies are high, at least for unilat-
eral retinoblastoma, which implies that patient recruitment for clinical trials is very challenging19. This, in turn, 
makes setting up large clinical trials to validate novel treatment strategies arduous. Rapid and highly penetrant 
pre-clinical disease models for retinoblastoma are therefore extremely valuable for drug validation efforts, which 
can then be translated to front-line treatments30.
Animal models for retinoblastoma have been described before in both mice and zebrafish. An orthotopic ret-
inoblastoma transplantation model in zebrafish exhibiting invasiveness and metastasis has been used for screen-
ing anti-cancer compounds31,32. Besides, it was shown that six established retinoblastoma mouse strains, all based 
on the simultaneous inactivation of the Rb1 and Rbl1 genes, exhibited extensive overlap and intermixing of their 
gene expression profile22. The authors subsequently demonstrated through principal component analysis that 
most of the difference between the gene profiles of human and mouse retinoblastoma cells were within a single 
dimension. This implies that the Chx10-Cre; Rb1Lox/Lox; Rbl1−/− mice model, and the five others, are suitable mod-
els closely mimicking the molecular background of clinical retinoblastoma. By extension, this strongly suggests 
that modeling retinoblastoma by knocking out Rb1 and Rbl1 in mice is a suitable approach, which we expect to be 
similar in other animals models, such as Xenopus tropicalis.
We believe that our retinoblastoma model, the first genuine genetic retinoblastoma model in a non-mammal 
and the first CRISPR/Cas9 mediated cancer model in Xenopus tropicalis, can provide several unique advantages. 
Firstly, as a genuine genetic model it competes well with the orthotopic zebrafish models. Secondly, our model 
generated with the second gRNA pair (rb1cr2 and rbl1cr2), with median time of 69 days until retinoblastoma devel-
opment, shows faster tumor emergence kinetics than the established Chx10-Cre; Rb1Lox/Lox; Rbl1−/−; p53−/− model 
(Median time until RB development: 100 ± 42.3 days)13. Please note that the Xenopus median time until retino-
blastoma development is counted as days post-fertilization, whilst with any mice model 21 days (gestation time) 
should be added to the reported median time. Considering that this mouse model has already been successfully 
employed for pre-clinical studies, this implies that our Xenopus model could also be used for such purposes33. 
Additionally, the extensive brood size and external development of X. tropicalis, coupled with the ease by which 
CRISPR/Cas9 can be introduced by standard micro-injection, allows generation of several hundreds of rb1/rbl1 
mosaic mutant animals in one mating. These cohort sizes easily surpass those feasible in murine studies, without 
the need for time-consuming breeding. Next to this, unilateral injection in two-cell X. tropicalis embryos provides 
the unique possibility to generate Xenopus rb1/rbl1 mosaic mutant animals that exhibit essentially one wild-type 
eye and one mosaic mutant eye. This implies that in a drug screening effort, one can immediately assess the effect 
of the drug not only on the retinoblastoma, but also for toxicity on normal retinal cell homeostasis.
Finally and importantly, the presented X. tropicalis retinoblastoma model provides unique possibilities for fast 
exploration of the impact of inactivating modifier (or effector) genes on cancer development by multiplex CRISPR/
Cas9 gRNA injections. This in contrast to low latency mice models (e.g. Chx10-Cre; Rb1Lox/Lox; Rbl1−/−; p53−/−) 
where targeting an additional locus, on top of the existing modified ones, becomes a difficult feat to accomplish 
from a breeding and locus segregation perspective. Note that X. tropicalis is a true diploid and there is very high 
synteny between the human and the X. tropicalis genomes, which greatly facilitates the identification of the frog 
orthologs for most human genes of interest24. We have previously shown that multiplexed gene targeting in devel-
oping Xenopus tumors is possible23. Moreover, we have shown here that we are able to target three distinct loci 
(rb1, rbl1 and syk) by triple multiplex CRISPR/Cas9 at genome editing levels that are more or less similar for each 
locus. Taken together, we thus hypothesize that retinoblastoma developing in these triple mutants should show 
INDELs for all three targeted loci, unless there is negative selection for modification of the modifier gene (Fig. S8). 
For this rb1, rbl1 and a modifier are targeted by triple multiplex CRISPR/Cas9 and retinoblastomas should be 
(micro)dissected. If bi-allelic modifier gene mutations can be detected in (micro)dissected retinoblastoma, this 
indicates that the modifier is not critical for tumor formation. The other possibility is that bi-allelic modifier gene 
mutations are never detected in (micro)dissected retinoblastoma. This provides strong evidence that the modifier 
is critical in retinoblastoma tumorigenesis, due to apparent negative selection. This implies, like stated above, 
that this modifier is critical in retinoblastoma tumorigenesis and that it might represent a very attractive novel 
drug target. The fact that such an experiment can already be performed in 2–3 months opens up opportunities 
for high-throughput therapeutic target identification. Such targeted drug discovery efforts can lead to fast and 
rational drug design and development of novel strategies for treatment of retinoblastoma.
We firmly believe that non-mammalian vertebrate cancer models like the one presented here, which pro-
foundly recapitulate the clinical situation, will be key in order to have the biomedical community conform to the 
requests from the public and policymakers to reduce the amount of mammals used in pre-clinical studies. Whilst 
models with closer evolutionary distance to humans will always be necessary for validating studies performed 
in those models with further evolutionary distance, we feel that non-mammalian vertebrate models can provide 
significant advantages during earlier stages of drug discovery and for rapid therapeutic target identification.
Material and Methods
gRNA design and generation. Rb1cr1 gRNA was designed with the Doench, Hartenian algorithm34. Rbl1cr1 
gRNA was designed with the CCTop tool35. Rb1cr2, rbl1cr2 and syk gRNAs were designed with the CRISPRScan 
algorithm36.
In this study, the following sequences were targeted. Rb1cr1 5′ -AGACAAACAAGGGAACGGGA-3′, 
rb1cr2 5 ′  -GCTGTATGAT TGTGCTGTACCGG-3 ′ ,  rbl1cr1 5 ′  -ATAT T TCAAAACCCTCACG-3 ′ , 
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rbl1cr2 5′ -TGGGCTTGCGCGCTGATGTGGGG-3, syk 5′ -TGGGTAGGAGGTGCTGGACATGG-3′ . 
A PCR-based strategy for generating DNA templates for in-vitro gRNA transcription was employed as 
described before37. The 5′ primer contains the target sequence and has the form 5′ - GAAATTAATACGA 
CTCACTATAGG(N)16–20 GTTTTAGAGCTAGAAATAGC-3′ whilst the 3′ primer is common to all 
gRNA templates and is as follows 5 ′  A AA AG CA CC GA CT CG GT GC CA CT TT TT CA AG TT GA TA 
AC GG AC TA GC CT TA TT TT AACTTGCTATTTCTAGCTCTAAAAC-3′. Assembly reaction was performed 
with Phusion high-fidelity polymerase (Thermo-scientific). DNA templates were purified by phenol-chloroform 
extraction/NaOAc precipitation. In-vitro transcription of the gRNA was performed with either the 
MEGAshortscript™ T7 Transcription Kit (ThermoFisher Scientific) or HiScribe™ T7 High Yield RNA Synthesis 
Kit (New England Biolabs) and gRNAs were purified by phenol-chloroform extraction/NH4OAc precipitation. 
Concentrations were determined by Nanodrop (Thermo-Scientific).
Recombinant NLS-Cas9-NLS generation. pX330-U6-Chimeric_BB-CBh-hSpCas9 was a 
gift from Feng Zhang (Addgene plasmid #42230)38. Cloning from this plasmid led to generation of 
pLHM36NLS(S)-Cas9(SP)-NLS(N). Subsequently, recombinant NLS-Cas9-NLS was expressed in the Escherichia 
coli strain BL21codon + pICA2 after transformation with pLHM36NLS(S)-Cas9(SP)-NLS(N) and purified. The 
pLHM36NLS(S)-Cas9(SP)-NLS(N) plasmid description, protein expression induction and protein purification 
strategies are shown in Supplementary data.
Xenopus tropicalis microinjection. Wild-type Xenopus tropicalis female and male were primed with 20U 
and 10U PREGNYL© human chorionic gonadotropine (hCG) (Merck), respectively. Natural matings were set-up 
2 days later, after boosting the female and male with 150U and 100U of hCG, respectively. Embryos were collected 
as described before39. Embryos were unilaterally injected at the two cell stage with 1nl of injection mix containing 
combinations of gRNA and NLS-Cas9-NLS (VIB Protein Service Facility, UGent) as shown in Supplementary 
Table S2. All experiments were approved by the Ethical Committee for Animal Experimentation from Ghent 
University, Faculty of Science and VIB-Site Ghent (Ethical Approval #2013-076). All methods were carried out in 
accordance with the relevant guidelines set out by this committee.
DNA extraction and targeted deep sequencing. For analyzing the genome editing efficiency tadpoles, 
tissue or tumors were incubated overnight at 55 °C in lysis buffer (50 mM Tris pH 8.8, 1 mM EDTA, 0.5% Tween-
20, 200 μ g/ml proteinase K). For assessing total genome editing efficiency for a specific injection setup we pooled 
a minimum of 5 stage 46 tadpoles and performed lysis by proteinase K treatment. The locus of interest was ampli-
fied by PCR with the respective primer pairs as shown in Table S3. Targeted deep sequencing of PCR products was 
performed using a previously described workflow40,41. Indel frequency data and sequence variants for all targeted 
deep sequencing are shown in Supplementary Table S1.
Imaging, histology and immunohistochemistry. All pictures of euthanized and living tadpoles were 
taken with a Carl Zeiss StereoLUMAR.V12 stereomicroscope. Complete heads of euthanized tadpoles were dis-
sected, fixed in 4% PFA (paraformaldehyde) and decalcified by Morse’s solution (10% sodium citrate and 22.5% 
formic acid) for 7 hours up to overnight (depending on age of specimen). Tissue samples were subsequently dehy-
drated and embedded in paraffin. Tissue sections of 5 μ M were cut by microtome, rehydrated and hematoxylin 
and eosin stained with a Varistain™ 24-4 Automatic Slide Stainer (Thermo-Scientific). Images were captured with 
an Axio Scan.Z1 (Zeiss, Germany). Images were acquired with a 20X Plan-Apochromat 0.8 NA dry objective, 
using a Hitachi HV-F202SCL camera. For PCNA immunohistochemistry, antigen retrieval was performed using 
the PickCell 2100-Retriever (ProteoGenix) in citrate buffer (10 mM citric acid, 0.1% Tween-20, pH 6). Slides were 
subsequently blocked with blocking buffer (3% goat serum, 1% BSA, 0.1% Tween-20) and incubated overnight 
with PCNA antibody (Clone PC10-Dako) diluted 1/500 in blocking buffer at 4 °C. Detection was performed with 
secondary goat anti-mouse dylight-594 and counter-staining was performed with Hoechst-33342. Sections were 
subsequently imaged using a Leica TCS LSI zoom confocal microscope.
Genotyping of tumors by laser capture microdissection. Five μ M sections containing tissues of 
interest were rehydrated, stained with hematoxylin and eosin and dehydrated to 100% EtOH. Cells/Tissues were 
microdissected by laser pressure catapulting (LPC) using a P.A.L.M. MicroBeam laser microdissection system 
(P.A.L.M. Zeiss Microlaser Technologies, Munich, Germany). DNA was purified from micro dissected cells with 
the QIAamp DNA Micro Kit (Qiagen), the appropriate genomic regions containing the CRISPR/Cas9 cut sites 
were PCR amplified and targeted deep sequencing was performed as described above.
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